Ankylosing spondylitis (AS) is a long-term disease process that affects the axial joints near the midline, especially the spine and sacroiliac joints (the joints located at the lowest end of the spine, called the sacrum and the pelvis). AS causes eventual fusion of the spine. Peripheral joints, such as the hips and knees, may be involved; the arms are almost never involved.
The primary disease process involves inflammation where the ligaments and tendons insert into the bones. The disorder predominantly affects the bones, causing rigidity of the spine. It may also involve the hips, knees, and occasionally the small joints of the feet. Inflammation of the connective tissue of the undersurface of the foot (plantar fasciitis) may also occur.
Nonskeletal problems associated with AS may include inflammation of the iris or uvea (the layer of the eye below the white of the eye), and less commonly inflammation of the aorta, pulmonary fibrosis, amyloidosis (deposition of a complex protein in organs and tissues), and inflammatory bowel disease.
Neurological complications include C1-C2 subluxation (partial displacement of the first and second cervical vertebrae), a tendency for spinal fractures with minor trauma, spinal stenosis (narrowing) in the cervical (neck) or lumbar (low back) regions, chronic inflammatory cauda equina syndrome (compression of the low back nerve roots, which causes paralysis and cuts off sensation), and radiculopathy (shooting pain caused by pressure on the nerves) secondary to fracture or compression of the nerve roots.
In the general population, 1.4% people are affected with AS. AS is more common in males than in females. The male-to-female ratio is approximately 3:1. The peak onset is in adolescents and young adults aged 15-30 years.| Printer-Friendly Format | | | Email to a Friend |
Get the latest treatment options
Cymbalta is approved for the treatment of fibromyalgia.
Important Safety Information
Cymbalta® (duloxetine HCl) is approved for the treatment of depression and generalized anxiety disorder, and for the management of diabetic peripheral neuropathic pain and fibromyalgia.
Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, unusual changes in behavior, thoughts of suicide, anxiety, agitation, panic attacks, difficulty sleeping, irritability, hostility, aggressiveness, impulsivity, restlessness, or extreme hyperactivity. Call your healthcare provider right away if you have thoughts of suicide or if any of these symptoms are severe or occur suddenly. Be especially observant within the first few months of antidepressant treatment or whenever there is a change in dose.
You should not take Cymbalta if:
Before starting Cymbalta, tell your healthcare provider:
While taking Cymbalta, tell your healthcare provider:
If you have any questions, talk to your healthcare provider before taking Cymbalta.
The most common side effect of Cymbalta was nausea. For most people who had it, the nausea was mild to moderate. Other common side effects included dry mouth, sleepiness, constipation, decreased appetite, and, increased sweating. This is not a complete list of side effects.
Spondyloarthritis or spondyloarthropathy refers to a group of chronic inflammatory conditions affecting the joints, tendon and ligament attachments, and sometimes nonskeletal structures.
|